IMNN-001 Shows 14.7-Month OS Benefit in Phase 2, Enrollment Ahead of Plan
IMNN is trading near its 52-week low of $1.33 (5.3% above the low).
Summary
Imunon's R&D Day revealed final Phase 2 OVATION 2 overall survival data: 45.1 months for IMNN-001 plus chemo vs 30.4 months for chemo alone, a 14.7-month difference that widened from the 11.1-month signal reported in July 2024. The PARP inhibitor maintenance subgroup showed an even larger 24.2-month improvement (65.6 vs 41.4 months). Updated MRD study data also favored IMNN-001: 44.4% vs 66.7% MRD-positive rate, 87.5% vs 62.5% ctDNA clearance, and 100% vs 56% no evidence of disease. OVATION 3 enrollment is running at 0.5 patients/site/month vs the 0.3 planning assumption, with completion targeted for Q1 2029. Two pre-planned interim analyses could support an earlier BLA if the survival signal crosses the threshold. This is the strongest efficacy data yet for IMNN-001 and directly de-risks the pivotal trial, though the company's $6.9M cash position and going concern warning remain critical constraints.
At the time of this announcement, IMNN was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.33 to $5.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.